deltatrials
Recruiting PHASE2 INTERVENTIONAL 5-arm NCT06019130

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo)

Nivolumab in Combination With Cisplatin and 5-Fluorouracil as Induction Therapy in Children and Adults With EBV-positive Nasopharyngeal Carcinoma

Sponsor: Deutsche Krebshilfe e.V., Bonn (Germany)

Updated 5 times since 2023 Last updated: May 14, 2024 Started: Jan 10, 2023 Primary completion: Jan 9, 2026 Completion: Jan 9, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06019130, this PHASE2 trial focuses on Nasopharyngeal Cancer and Nasopharyngeal Carcinoma and remains actively recruiting participants. Sponsored by Deutsche Krebshilfe e.V., Bonn (Germany), it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Sep 2023 – ~Jun 2024 · 9 months · monthly snapshotRecruiting~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotRecruiting~Sep 2025 – present · 12 months · monthly snapshotRecruiting

Change History

5 versions recorded
  1. Sep 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Sep 2023 — Jun 2024 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Deutsche Krebshilfe e.V., Bonn (Germany)
  • German Society for Pediatric Oncology and Hematology GPOH gGmbH
Data source: German Society for Pediatric Oncology and Hematology GPOH gGmbH

For direct contact, visit the study record on ClinicalTrials.gov .